ライフサイエンスコーパス: Kaplan-Meier curve

1 cumulative incidence function curve with the Kaplan-Meier curve.

2 Cumulative TB risk was estimated with Kaplan-Meier curves.

3 Survival was assessed using Kaplan-Meier curves.

4 imes to event outcomes were summarized using Kaplan-Meier curves.

5 nadjusted observed survival was inspected by Kaplan-Meier curves.

6 groups are compared using log-rank test and Kaplan-Meier curves.

7 and the prognostic value was determined with Kaplan-Meier curves.

8 dysfunction and failure) were compared using Kaplan-Meier curves.

9 elative CBV and time to progression by using Kaplan-Meier curves.

10 nd pouch retention rates were analyzed using Kaplan-Meier curves.

11 had and did not have PTNB was compared using Kaplan-Meier curves.

12 iers versus wild types was examined by using Kaplan-Meier curves.

13 was compared among white and Hispanics using Kaplan-Meier curves.

14 umulative incidence of advanced neoplasia by Kaplan-Meier curves.

15 fully describes the actual survival based on Kaplan-Meier curves.

16 luation of which was by log rank analysis of Kaplan-Meier curves.

17 ome left ventricular ejection fraction using Kaplan-Meier curves.

18 Mortality over time was expressed with Kaplan-Meier curves.

19 n the HM3 and HVAD cohorts was compared with Kaplan-Meier curves.

20 using Fine and Gray cumulative incidence and Kaplan-Meier curves.

21 pring age was determined using meta-analytic Kaplan-Meier curves.

22 alysis, univariate analysis or directly from Kaplan-Meier curves.

23 ere analyzed using Cox-regression models and Kaplan-Meier curves.

24 summary statistics extracted from individual Kaplan-Meier curves.

25 were generated based on data extracted from Kaplan-Meier curves.

26 ulative 5-year mortality were estimated with Kaplan-Meier curves.

27 nitial 48 hours after hospital arrival using Kaplan-Meier curves.

28 to MRI response category were assessed using Kaplan-Meier curves.

29 imized follow-up intervals were derived from Kaplan-Meier curves.

30 rgery was calculated for illustration of the Kaplan-Meier curves.

31 Survival was analyzed using Kaplan-Meier curves.

32 ll survival time and cancer recurrence using Kaplan-Meier curves.

33 Survival was described using Kaplan-Meier curves.

34 Survival was analyzed with Kaplan-Meier curves.

35 ormed by descriptive methods and survival by Kaplan-Meier curves.

36 hted Cox proportional hazards regression and Kaplan-Meier curves.

37 breast cancer diagnosis was plotted by using Kaplan-Meier curves.

38 d using C statistics, calibration plots, and Kaplan-Meier curves.

39 g-term allograft survival was compared using Kaplan-Meier curves.

40 Kaplan-Meier curve analysis indicated that the AS group

41 A Kaplan-Meier curve analysis revealed that the cumulative

42 lysis to determine adenovirus incidence, and Kaplan-Meier curve analysis to determine the timing of e

43 Cox multivariate regression analysis, Kaplan-Meier curve analysis, and receiver operating char

44 In Kaplan-Meier curve analysis, the median times to acquisi

45 ssociated with poor survival, as revealed by Kaplan-Meier curves analysis.

46 Patient survival was assessed using Kaplan-Meier curves analysis.

47 Kaplan-Meier curves analyzed the proportion of eyes that

48 d prognostic factors were assessed using the Kaplan-Meier curve and Cox proportional hazard model.

49 Kaplan-Meier curve and multivariable Cox regression mode

50 and overall survival (OS) was assessed with Kaplan-Meier curves and a corresponding log-rank test fo

51 Survival analysis was conducted using Kaplan-Meier curves and a proportional hazards generaliz

52 Kaplan-Meier curves and adjusted Cox models were used to

53 Survival analysis employed Kaplan-Meier curves and adjusted Cox proportional hazard

54 We compared survival with Kaplan-Meier curves and analyzed the association between

55 We analysed cumulative rupture rates with Kaplan-Meier curves and assessed predictors with Cox pro

56 by stratified univariate log-rank test with Kaplan-Meier curves and by multivariate Cox proportional

57 ination and calibration were performed using Kaplan-Meier curves and calibration plots.

58 rtality for each tertile was determined with Kaplan-Meier curves and compared by the modified Peto-Pe

59 We created Kaplan-Meier curves and constructed multivariable Cox pr

60 urvival free from an AE was calculated using Kaplan-Meier curves and Cox hazard ratios were derived.

61 accine-targeted type; and 3) construction of Kaplan-Meier curves and Cox models to evaluate sequentia

62 Kaplan-Meier curves and Cox models were used to assess g

63 ospital all-cause mortality was evaluated by Kaplan-Meier curves and Cox proportional hazard modeling

64 OS and DFS analyses were performed using Kaplan-Meier curves and Cox proportional hazard models.

65 ther secondary end points were examined with Kaplan-Meier curves and Cox proportional hazard models.

66 tcome of all-cause mortality with unadjusted Kaplan-Meier curves and Cox proportional hazard models.

67 ree from adverse events was calculated using Kaplan-Meier curves and Cox proportional hazard ratios w

68 Statistical analysis was performed using Kaplan-Meier curves and Cox proportional hazard ratios.

69 Kaplan-Meier curves and Cox proportional hazards models

70 IPTW-adjusted Kaplan-Meier curves and Cox proportional hazards models

71 Kaplan-Meier curves and Cox proportional hazards models

72 Kaplan-Meier curves and Cox proportional hazards models

73 Kaplan-Meier curves and Cox proportional hazards models

74 e and associated factors were assessed using Kaplan-Meier curves and Cox proportional hazards models,

75 Prognostic factors were evaluated using Kaplan-Meier curves and Cox proportional hazards models.

76 erapy/CCRT PET/CT imaging was examined using Kaplan-Meier curves and Cox proportional hazards models.

77 Statistical analysis was performed using Kaplan-Meier curves and Cox proportional hazards ratios.

78 Survival analysis was performed using Kaplan-Meier curves and Cox proportional hazards regress

79 lity of treatment weighting (IPTW) -adjusted Kaplan-Meier curves and Cox proportional hazards regress

80 ity and morbidity events were analyzed using Kaplan-Meier curves and Cox proportional hazards regress

81 Disease-free survival was examined using Kaplan-Meier curves and Cox proportional hazards regress

82 lity of treatment weighting (IPTW) -adjusted Kaplan-Meier curves and Cox regression analyses were use

83 Outcomes analysis was performed using Kaplan-Meier curves and Cox regression analysis.

84 Outcome analysis was performed using Kaplan-Meier curves and Cox regression including fat-rel

85 Kaplan-Meier curves and Cox regression modeling were use

86 Survival analysis included Kaplan-Meier curves and Cox regression models.

87 OS examined with Kaplan-Meier curves and Cox regression models.

88 We further used Kaplan-Meier curves and Cox regression to assess differe

89 We used Kaplan-Meier curves and Cox regression to evaluate the a

90 Kaplan-Meier curves and Cox regression were used to asse

91 Kaplan-Meier curves and Cox regression were used to inve

92 site, was compared with regional data using Kaplan-Meier curves and Cox regression.

93 Survival analysis included Kaplan-Meier curves and Cox regressions.

94 Kaplan-Meier curves and Cox-proportional hazard regressi

95 Kaplan-Meier curves and generalised estimating equations

96 We used Kaplan-Meier curves and hazard ratios (HRs) for time to

97 Kaplan-Meier curves and log-rank test were used to compa

98 Kaplan-Meier curves and log-rank testing were used to co

99 Kaplan-Meier curves and log-rank tests evaluated the pro

100 OS and updated PFS data are presented using Kaplan-Meier curves and log-rank tests stratified for ho

101 Kaplan-Meier curves and log-rank tests were applied to d

102 Kaplan-Meier curves and log-rank tests were used to asse

103 Kaplan-Meier curves and log-rank tests were used to eval

104 Survival for CABG and PCI was compared using Kaplan-Meier curves and log-rank tests.

105 als for the three groups were compared using Kaplan-Meier curves and log-rank tests.

106 G and PCI survival rates were compared using Kaplan-Meier curves and log-rank tests.

107 Graft survival rates were compared using Kaplan-Meier curves and log-rank tests.

108 Long-term survival was assessed by Kaplan-Meier curves and log-rank tests.

109 DFS and OS were analyzed using Kaplan-Meier curves and multiple Cox regression.

110 Kaplan-Meier curves and multivariable Cox models (ie, ad

111 astasis-free survival were investigated with Kaplan-Meier curves and multivariable Cox models.

112 Kaplan-Meier curves and multivariable Cox proportional h

113 Kaplan-Meier curves and multivariable Cox proportional h

114 Kaplan-Meier curves and multivariable Cox proportional h

115 Kaplan-Meier curves and multivariable Cox-regression mod

116 Events were analyzed using Kaplan-Meier curves and multivariable-stratified Cox pro

117 Kaplan-Meier curves and proportional hazard ratios from

118 me to sputum culture conversion (TSCC) using Kaplan-Meier curves and stratified Cox regression.

119 te of ACM or first CVH were plotted by using Kaplan-Meier curves and summarized with a stratified Cox

120 Kaplan-Meier curves and survival models were assessed wi

121 between different groups was compared using Kaplan-Meier curves and the log rank test.

122 Kaplan-Meier curves and the log-rank test were used to e

123 Using Kaplan-Meier curves and the log-rank test, we compared m

124 , Gleason scores, and stage were analyzed by Kaplan-Meier curves and the log-rank test.

125 iedman's test, and we analysed survival with Kaplan-Meier curves and the log-rank test.

126 Survival has been determined from Kaplan-Meier curves and treatment comparisons made with

127 Kaplan-Meier curves and univariable and multivariable Co

128 We calculated Kaplan-Meier curves and used adjusted Cox proportional-h

129 , using Cox proportional hazards regression, Kaplan-Meier curves, and calculation of Harrell's c inde

130 , prevalence- and bias-adjusted kappa value, Kaplan-Meier curves, and Cox proportional hazard models.

131 ver operating characteristic (ROC) analysis, Kaplan-Meier curves, and Cox proportional hazard regress

132 mes were assessed using frequency of events, Kaplan-Meier curves, and Cox proportional hazards regres

133 The log-rank test, Kaplan-Meier curves, and Cox regression compared surviva

134 Drug survival was depicted through Kaplan-Meier curves, and Cox regression models were used

135 Survival analysis was conducted using Kaplan-Meier curves, and Cox regression was used to iden

136 Cox regression analysis, Kaplan-Meier curves, and cross-validated receiver operat

137 Cox proportional hazard models, Kaplan-Meier curves, and z scores were applied to assess

138 with that of an inverse probability-weighted Kaplan-Meier curve applied after treating bacteremia as

139 The area under the curve of a conventional Kaplan-Meier curve applied to the observed data was comp

140 Kaplan-Meier curves are provided for each baseline facto

141 Kaplan-Meier curves assessed survival, and Wilson score

142 rable outcome derived from the time-to-event Kaplan-Meier curve at 10 years was 0.64 (95% CI 0.58-0.6

143 Discrimination using Kaplan-Meier curves, calibration curves, and bootstrap c

144 Kaplan-Meier curves censored at 10 y were generated for

145 Kaplan-Meier curves compared time to event data between

146 Survival analysis showed that Kaplan-Meier curves comparing dosage interruption to ong

147 Kaplan-Meier curves comparing those treated and not trea

148 sing a Cox hazards model, the log-rank test, Kaplan-Meier curves, competing-risks regression, and con

149 with all-cause mortality were studied using Kaplan-Meier curves, Cox proportional hazards regression

150 Actuarial survival analysis using Kaplan-Meier curves, Cox regression and competitive risk

151 sion of TZP or carbapenems was assessed with Kaplan-Meier curves, Cox-regression model, and estimatio

152 The Kaplan-Meier curves demonstrated improved arrhythmia-fre

153 Kaplan-Meier curves demonstrated least favorable surviva

154 9; logistic odds for events 0.44, p = 0.02); Kaplan-Meier curves demonstrated significant differences

155 Kaplan-Meier curves depict survival by nativity for Hisp

156 ox proportional hazards regression model and Kaplan-Meier curves determined whether black race affect

157 The Kaplan-Meier curves did not differ both for complete and

158 Kaplan-Meier curves did not show a difference in proport

159 o, 2.27 [95% CI, 1.84-2.82], P=6.3x10(-14)), Kaplan-Meier curves differed significantly between HFrEF

160 Amputation-free survival rate assessed with Kaplan-Meier curves differed through 12 months: 59% (41

161 g both the Cox proportional hazard model and Kaplan-Meier curves each show that the proposed method f

162 Kaplan-Meier curves estimated time to first development

163 Kaplan-Meier curves evaluated the impact of statin thera

164 were seen in most diagnostic groups, but the Kaplan-Meier curves flattened out over time.

165 Kaplan-Meier curve for overall survival revealed high ex

166 ty was estimated based on the area under the Kaplan-Meier curve for symptomatic grade 2 or greater fa

167 Moreover, the corresponding Kaplan-Meier curve for the end point of interest is unin

168 Kaplan-Meier curves for all-cause mortality were constru

169 CCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalizat

170 Kaplan-Meier curves for diagnosis of any cancer up to 10

171 Kaplan-Meier curves for ocular relapse-free survival (RF

172 Kaplan-Meier curves for overall survival (OS) were calcu

173 Kaplan-Meier curves for partially vaccinated and unvacci

174 During titration, the Kaplan-Meier curves for the combined end point of all-ca

175 The Kaplan-Meier curves for the probability of nonrecurrence

176 n model for recurrent time-to-event data and Kaplan-Meier curves for time to antibody negativity were

177 Kaplan-Meier curves for time to event for the primary ou

178 Kaplan-Meier curves for time to the secondary outcome of

179 rvival (TFS) was defined as the area between Kaplan-Meier curves for two conventional time-to-event e

180 Kaplan-Meier curves from the randomized clinical trials

181 Kaplan-Meier curves, Harrell's C statistic, receiver ope

182 Long-term survival was visualized with Kaplan-Meier curves, hazard ratios were calculated and p

183 Kaplan-Meier curves identified significant gene differen

184 al analysis demonstrates a divergence of the Kaplan-Meier curves in favor of patients in whom APBF wa

185 Estimated crude 10-year mortality based on Kaplan-Meier curves in mothers of infants with NAS was 5

186 e extracted from the text of articles or the Kaplan-Meier curves independently by investigators who w

187 Kaplan-Meier curves indicated that all-cause mortality w

188 nder the curve of 0.85 vs. 0.74 for BNP) and Kaplan-Meier curves (log rank: 17.5 vs. 9.95).

189 Kaplan-Meier curves (log-rank analyses) were used to est

190 immunohistochemistry were investigated using Kaplan-Meier curves, log rank tests, and Cox regression

191 Kaplan-Meier curves, log-rank analysis, and Cox proporti

192 sion-free survival (PFS) were compared using Kaplan-Meier curves, log-rank tests and Cox models.

193 database performed between 1991 and 2003 by Kaplan-Meier curves, log-rank tests, and Cox proportiona

194 Survival analysis was performed with the Kaplan-Meier curve method (log rank test; P < 0.05).

195 redictors of survival were analyzed with the Kaplan-Meier curve method (log-rank test) and multivaria

196 Kaplan-Meier curves of all-comer populations, subgroups

197 Kaplan-Meier curves of EAC incidence were stratified by

198 Kaplan-Meier curves of the incidence of motor vehicle co

199 r uniformity at a coarse scale value of 2.5, Kaplan-Meier curves of the proportion of patients withou

200 The Kaplan-Meier curves of TIA patients with DAPT and monoth

201 rence in 3-month survival was observed using Kaplan-Meier curves (P =.11).

202 At Kaplan-Meier curves, patients with LGE and without edema

203 Kaplan-Meier curves plot the duration of effect.

204 We estimated time to first pregnancy using Kaplan-Meier curves; pregnancy and HIV incidence were es

205 Kaplan-Meier curve reconstruction did not show significa

206 Early crossing of the overall survival Kaplan-Meier curves reflected a higher number of deaths

207 : 0.60; 95% CI: 0.45-0.80; P = 0.0005), with Kaplan-Meier curves separating at month 3 and continuing

208 At 4-year follow-up, the Kaplan-Meier curve showed an absolute difference in surv

209 The Kaplan-Meier curve showed that CCI-779 significantly inc

210 Kaplan-Meier curves showed 1-year survival after first s

211 Kaplan-Meier curves showed a significant higher 30-day m

212 Kaplan-Meier curves showed a significantly higher 30-day

213 Kaplan-Meier curves showed early, sustained separation b

214 Kaplan-Meier curves showed fewer patients with AA athero

215 Kaplan-Meier curves showed global allograft survival dif

216 Kaplan-Meier curves showed longer median disease-specifi

217 Kaplan-Meier curves showed patients with forced expirato

218 The Kaplan-Meier curves showed significant differences in fa

219 The adjusted Kaplan-Meier curves showed significantly lower survival

220 Kaplan-Meier curves showed that all four models effectiv

221 Kaplan-Meier curves showed that both high and low PIP4K2

222 Adjusted Kaplan-Meier curves showed that individuals with a FRS =

223 IPTW-adjusted Kaplan-Meier curves showed that median OS was significan

224 IPTW-adjusted Kaplan-Meier curves showed that median OS was significan

225 IPTW-adjusted Kaplan-Meier curves showed that median OS was significan

226 Kaplan-Meier curves showed that reduced Ks and prolonged

227 During a median follow-up of 2.3 years, Kaplan-Meier curves showed that survival free from both

228 Kaplan-Meier curve shows 86.5% and 94.6% (P=0.086) and p

229 The Kaplan-Meier curve shows a 4-year probability of develop

230 The Kaplan-Meier curve significantly favored TEVAR for the e

231 t important finding of the study was that in Kaplan-Meier curves stratified by mean dose, longer PFS

232 Kaplan-Meier curves stratified by sex and proviral load

233 On Kaplan-Meier curves, stratifying p16 by EBV status elimi

234 Log-rank tests on Kaplan-Meier curves suggested differences in graft and p

235 post-operative mortality was analyzed using Kaplan-Meier curve survival and Log-Rank tests.

236 CVE risk was estimated using Kaplan-Meier curves, the log-rank test, and Cox proporti

237 Survival rates computed from stage-specific Kaplan-Meier curves (time to melanoma-specific death) we

238 We used Kaplan-Meier curves to compare patient survival between

239 eveloped Cox proportional hazards models and Kaplan-Meier curves to compare women who underwent oopho

240 f IGF-1 and VEGF with overall survival (OS), Kaplan-Meier curves to estimate OS, and recursive partit

241 We used Kaplan-Meier curves to estimate the cumulative probabili

242 We used Kaplan-Meier curves to show graft survival.

243 SGLT-2i compared with DPP-4i and GLP-1RA and Kaplan-Meier curves to visualize fracture risk over time

244 With regard to overall mortality (Kaplan-Meier curves), univariate analysis also revealed

245 Kaplan Meier curves was used for survival analysis and C

246 The area under each Kaplan-Meier curve was estimated by the 36-month restric

247 Kaplan-Meier curve was significantly different between g

248 Kaplan-Meier curve was used to estimate patients' probab

249 A Kaplan-Meier curve was used to estimate the probability

250 Kaplan-Meier curve was used to examine cumulative risk f

251 bility of VT/VF: two-year risk of VT/VF from Kaplan-Meier curves was 40% in highest quartile versus 2

252 Valve survival analysis (Cox regression and Kaplan-Meier curves) was used to study the natural progr

253 Kaplan Meier curves were plotted for each derived phenot

254 The Cox proportional-hazards model and Kaplan-Meier curve were used to evaluate the association

255 Cox proportional hazard models and Kaplan-Meier curves were applied to assess the impact of

256 Kaplan-Meier curves were compared by using log-rank test

257 Kaplan-Meier curves were constructed for the time to fir

258 Kaplan-Meier curves were constructed to analyze time-to-

259 Kaplan-Meier curves were constructed to assess survival

260 Kaplan-Meier curves were constructed to compare survival

261 Kaplan-Meier curves were constructed to determine late r

262 Kaplan-Meier curves were constructed to evaluate limb sa

263 Kaplan-Meier curves were constructed to examine median t

264 Kaplan-Meier curves were created for presence of ER and

265 Kaplan-Meier curves were created to assess overall freed

266 Mortality and Kaplan-Meier curves were estimated for each wealth quart

267 ty for Medical Oncology meetings' libraries, Kaplan-Meier curves were extracted from phase 3 clinical

268 For each of these primary endpoints, Kaplan-Meier curves were generated and log-rank tests we

269 Kaplan-Meier curves were generated by cohort for time un

270 Kaplan-Meier curves were generated for survival analysis

271 Kaplan-Meier curves were generated to assess differences

272 Kaplan-Meier curves were generated to compare 1-y surviv

273 Kaplan-Meier curves were generated to compare the cumula

274 Kaplan-Meier curves were generated to examine recipient

275 We found that survival estimates from the Kaplan-Meier curves were largely congruent with those of

276 Kaplan-Meier curves were plotted to compare survival rat

277 Kaplan-Meier curves were plotted to determine the incide

278 Cumulative incidence Kaplan-Meier curves were reported for response, clinical

279 Cox regression analysis and Kaplan-Meier curves were used for analysis.

280 Kaplan-Meier curves were used for the presentation of un

281 Cox proportional hazards models and Kaplan-Meier curves were used to assess the association

282 Predictive Kaplan-Meier curves were used to compare the linear pred

283 Kaplan-Meier curves were used to compare the unadjusted

284 grouped using propensity score methods, and Kaplan-Meier curves were used to compare time to measles

285 Kaplan-Meier curves were used to depict persistence over

286 Kaplan-Meier curves were used to estimate distant-diseas

287 Kaplan-Meier curves were used to estimate overall surviv

288 Kaplan-Meier curves were used to estimate overall surviv

289 Kaplan-Meier curves were used to estimate progression-fr

290 Kaplan-Meier curves were used to estimate survival.

291 Kaplan-Meier curves were used to estimate the cumulative

292 Kaplan-Meier curves were used to evaluate prognostic val

293 Kaplan-Meier curves were used to explore the association

294 Kaplan-Meier curves were used to visualize mortality str

295 method demonstrated similar c-statistics and Kaplan-Meier curves when used in survival analyses.

296 Multivariate pooled Kaplan-Meier curves with 95% confidence intervals, based

297 e-bleeding free survival was evaluated using Kaplan-Meier curves with log rank test, whilst predictor

298 Graft survival was evaluated using Kaplan-Meier curves with log-ranks in individuals who un

299 atients was reconstructed from the published Kaplan-Meier curves with the aid of a computer vision pr

300 Individual patient data were extracted from Kaplan-Meier curves with WebPlotDigitizer version 5 and